MedTrace Logo

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

NCT00973076 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2011-06-15

No results posted yet for this study

Summary

The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.

Conditions

Interventions

DRUG

AZD8055

Tablets, orally administered, twice daily

Sponsors & Collaborators

Principal Investigators

  • Ian Smith · AstraZeneca

  • Tomohide Tamura · National Cancer Center Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00973076 on ClinicalTrials.gov